Russian Heart Failure Journal 2010year Opportunities for application of various doses of coenzyme Q10 in patients with chronic heart failure

To access this material please log in or register

Register Authorize

Opportunities for application of various doses of coenzyme Q10 in patients with chronic heart failure

Sizova J. M., Farafonova T. N., Medvedev O. S., Kalenikova E. I., Korotaeva A. L.

Keywords: quantitative analysis, coenzyme Q10, CHF

DOI: 10.18087/rhfj.2010.4.1351

Background. One of possible ways of influence on symptoms and quality of life in patients with CHF is to correct existing disorders of myocardial metabolism. Coenzyme Q10 (CoQ10) is a promising drug. Objective. To determine optimal dose of CoQ10 for treatment of patients with CHF receiving standard therapy. Materials and methods. The study included 24 patients with CHF FC II-III (16 men and 8 women, average age 62 years), complicating the course of CAD. All patients were divided into 3 groups: first group additionally to standard therapy received CoQ10, 60 mg (2 ml of "Qudesan"), 2nd group – CoQ10, 90 mg (3 ml of "Qudesan"), 3d group – CoQ10, 120 mg (4 ml of "Qudesan"). Follow-up lasted for 4 weeks. Efficacy and tolerability were evaluated by dynamics of clinical manifestations of CHF, CHF FC, exercise tolerance, 6 min walk test. CoQ10 plasma level was measured by high performance liquid chromatography with electrochemical detection. Results. Wide variation of CoQ10 initial concentration (from 183 to 913 ng/ml, on average – 489 ng/ml) was observed in patients with CHF. Evaluation of dynamics of CoQ10 plasma level showed that there was significant increase of CoQ10 blood level in all 3 groups of patients with CHF treated with different doses. Regardless of the dose (60, 90 or 120 mg/day), magnification of CoQ10 plasma level was about the same: 2.3 in patients receiving 60 mg/day, 2.4 in patients receiving 90 and 120 mg/day. Thus, CoQ10 60–120 mg a day (which corresponds to 2.4 ml of study drug) within 4 weeks leads to a significant increase of CoQ10 plasma level. No significant difference in dynamics of CoQ10 level depending on the drug’s dose was revealed. The optimal dose of CoQ10 in combined pharmacotherapy in patients with CHF is 60 mg a day. Adding CoQ10 to standard therapy in patients with CHF results in increased exercise tolerance according to 6 min walk test, improved general health, reduced dyspnea and heart pain.
  1. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: Framingham study. J Am Coll Cardiol. 1993;22 (4 suppl A):6A-13A.
  2. Горохова С. Г., Сизова Ж. М. Фармакотерапия хронической сердечной недостаточности в амбулаторно-поликлинической практике врача. Учебное пособие. – М.: ИД "МЕДПРАКТИКА-М", 2008. – с. 85.
  3. Ольбинская Л. И., Морозова Т. Е., Сизова Ж. М., Вартанова О. А. и др. Фармакотерапия хронических сердечно-сосудистых заболеваний: Руководство для врачей. – М.: Медицина, 2006. – 386 с.
  4. Лангсьен П. Х., Лангсьен А. М. Медицинское применение ингибиторов ГМГ-КоА-редуктазы и сопутствующий дефицит коэнзима Q10. РМЖ. 2007;15 (9):747–751.
  5. Sander S, Coleman CI, Patel AA et al. The impact of coenzyme Q10 on systolic function in patients with chronic heart failure. J Card Fail. 2006;12 (6):464–472.
  6. Аронов Д. М. Значение коэнзима Q10 в кардиологии. РМЖ. 2007;15 (20):1484–1488.
  7. Медведев О. С., Каленикова Е. И., Городецкая Е. А., Шашурин Д. А. Коэнзим Q10 в кардиологической практике – теоретические основы и результаты клинических исследований. РМЖ. 2009;17 (18):1177–1181.
  8. Аронов Д. М. Что важно знать практическому врачу об убихиноне (коэнзим Q10). Антиоксидантный препарат Кудесан. Применение в кардиологии (Часть 2). 2006,4–19.
  9. Ferrari R, Agnoletti L, Comini L et al. Oxidative stress during myocardial ischaemia and heart failure. Eur Heart J. 1998;19 (Suppl B):B2–11.
  10. Mortensen SA. Perspectives on therapy of cardiovaskular disease with coenzyme Q10 (ubiquinone). Clin Investig. 1993;71 (8 Suppl):S116–123.
  11. Soja AM, Mortensen SA. Treatment of congestive heart failure with coenzyme Q10 illuminated by meta-analyses of clinical trials. Mol Aspects Med. 1997;18 (Suppl):S159–168.
  12. Rosenfeldt FL, Haas SJ, Krum H et al. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. J Hum Hypertens. 2007;21 (4):297–306.
  13. Judy WV, Hall JH, Toth PD, Folkers K. Double blind-double crossover study of coenzyme Q10 in heart failure, in: Biomedical and Clinical Aspects of Coenzyme Q, (Vol. 5), K. Folkers and Y. Yamamura, eds, Elsevier, Amsterdam, 1986, pp. 315–323.
  14. Munkholm K, Hansen H, Rasmussen K. Coenzyme Q10 treatment in serious heart failure. Biofactors. 1999;9 (2-4):285–289.
  15. Molyneux SL, Florkowski CM, George PM et al. Coenzyme Q10: an independent predictor of mortality in chronic heart failure. J Am Coll Cardiol. 2008;52 (18):1435–1441.
  16. Tang PH, Miles MV, DeGrauw A et al. HPLC analysis of reduced and oxidized coenzyme Q10 in human plasma. Clin Chem. 2001;47 (2):256–265.
  17. Khatta M, Alexander BS, Krichten CM et al. The effect of coenzyme Q10 in patients with congestive heart failure. Ann Intern Med. 2000;132 (8):636–640.
  18. Morisco C, Nappi A, Argenziano L et al. Noninvasive evaluation of cardiac hemodynamics during exercise in patients with chronic heart failure: effects of short-term coenzyme Q10 treatment. Mol Aspect Med. 1994;15 (Suppl):S155–163.
  19. Hunt PJ, Richards AM, Nicholls MG et al. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol (Oxf). 1997;47 (3):287–296.
Sizova J. M., Farafonova T. N., Medvedev O. S. et al. Opportunities for application of various doses of coenzyme Q10 in patients with chronic heart failure. Russian Heart Failure Journal. 2010;11(4):218-222.

To access this material please log in or register

Register Authorize
Ru En